AS
Alek Safarian
CEO of ALSA Ventures
London, England
Overview
Alek Safarian is the CEO of ALSA Ventures in London, with a background in clinical trials, pharmaceutical industry, and regulatory affairs. Notable career highlights include serving as CEO of Novotech and holding a leadership role at Marion Merrell Dow in Asia-Pacific for scientific affairs.
Work Experience
CEO
2018 - Current
Member of the Board of Directors
1996 - 2017
CEO
1996 - 2017
Executive responsibility for day to day operations of the company, setting strategy together with management team and board, executing on the company's growth strategy.
Head, Scientific Affairs, Asia-Pacific
1990 - 1995
Based in Sydney, headed the regulatory affairs function and post-marketing research in 11 countries in the Asia-Pacific including Australia, China, Korea, Taiwan, and Singapore. Left MMD just before merger with Hoechst Roussel to found Novotech.
Regulatory Affairs Associate
1988 - 1990